Neha Anegondi, Yixuan Zou, Xuefeng Hou, Mohammadreza Negahdar, Dorothy Cheung, Paula Belloni, Alex De Crespigny, Alexandre Fernandez Coimbra
{"title":"Prognostic modeling in idiopathic pulmonary fibrosis using deep learning","authors":"Neha Anegondi, Yixuan Zou, Xuefeng Hou, Mohammadreza Negahdar, Dorothy Cheung, Paula Belloni, Alex De Crespigny, Alexandre Fernandez Coimbra","doi":"10.1183/13993003.congress-2023.oa4851","DOIUrl":null,"url":null,"abstract":"<b>Introduction:</b> Idiopathic pulmonary fibrosis (IPF) results in lung function decline. Prognostic models that accurately predict IPF progression could inform research studies and clinical care. <b>Objectives:</b> To develop deep learning (DL) models to predict IPF progression using baseline high-resolution computed tomography (HRCT). <b>Methods:</b> Retrospective analysis was performed on IPF patients enrolled in clinical trials (NCT01872689, NCT00287729, NCT01366209). Only baseline visit HRCT (non-contrast, supine position, full inspiration) were included in the analysis. The image dataset was split into training (n = 274) and holdout (n = 117). The training dataset was then split into 5 folds for cross-validation (CV). Two multi-task DL models [HRCT-only and multi-modal (HRCT and baseline clinical features)] were trained to simultaneously predict 3 endpoints: FVC at 1 year (mL), FVC change at 1 year (mL) and FVC slope (mL/year). The performance of the DL models were benchmarked with a linear model using baseline clinical features and evaluated using squared Pearson correlation coefficient (r<sup>2</sup>). <b>Results:</b> The multi-modal model had the best CV performance on training set with mean r<sup>2</sup> of 0.87, 0.13, and 0.14 for FVC at 1 year, FVC change at 1 year, and FVC slope. On the holdout set, the same model showed r<sup>2</sup> of 0.88, 0.11, and 0.12. In comparison, the benchmark model had a mean r<sup>2</sup> of 0.85, 0.05, and 0.05 on the training set and 0.89, 0.04, and 0.04 on the holdout set, respectively, for the 3 endpoints. <b>Conclusion:</b> HRCT scans add marginal value to baseline clinical features in predicting IPF progression. Further work is required to improve the performance of the current models for potential use in research studies and clinical care.","PeriodicalId":34850,"journal":{"name":"Imaging","volume":"37 1","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.congress-2023.oa4851","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Idiopathic pulmonary fibrosis (IPF) results in lung function decline. Prognostic models that accurately predict IPF progression could inform research studies and clinical care. Objectives: To develop deep learning (DL) models to predict IPF progression using baseline high-resolution computed tomography (HRCT). Methods: Retrospective analysis was performed on IPF patients enrolled in clinical trials (NCT01872689, NCT00287729, NCT01366209). Only baseline visit HRCT (non-contrast, supine position, full inspiration) were included in the analysis. The image dataset was split into training (n = 274) and holdout (n = 117). The training dataset was then split into 5 folds for cross-validation (CV). Two multi-task DL models [HRCT-only and multi-modal (HRCT and baseline clinical features)] were trained to simultaneously predict 3 endpoints: FVC at 1 year (mL), FVC change at 1 year (mL) and FVC slope (mL/year). The performance of the DL models were benchmarked with a linear model using baseline clinical features and evaluated using squared Pearson correlation coefficient (r2). Results: The multi-modal model had the best CV performance on training set with mean r2 of 0.87, 0.13, and 0.14 for FVC at 1 year, FVC change at 1 year, and FVC slope. On the holdout set, the same model showed r2 of 0.88, 0.11, and 0.12. In comparison, the benchmark model had a mean r2 of 0.85, 0.05, and 0.05 on the training set and 0.89, 0.04, and 0.04 on the holdout set, respectively, for the 3 endpoints. Conclusion: HRCT scans add marginal value to baseline clinical features in predicting IPF progression. Further work is required to improve the performance of the current models for potential use in research studies and clinical care.